KOD_OUT_1 [2025-04-17 15:50:47 -0400] 3765 Bytes | 1048 tokens | Cum: 1048 tkns (13.10% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 3:50:46 PM on Thu Apr 17, 2025 -0400, and I'm firing up the spotlight on Kodiak Sciences (KOD), moving from 2.3600 to 2.8474. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

--- COMPANY PROFILE ---
Company: Kodiak Sciences (KOD)
IPO: 2018-10-04 (6 Years Ago)
Market Cap: $114,991,388
Shares Outstanding: 52,750,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.

Here’s a list of headlines for Kodiak Sciences:

Apr-01-25 09:35AM - Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD)
Mar-28-25 09:45AM - Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus
Mar-27-25 04:01PM - Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
Mar-26-25 03:58PM - Is Kodiak Sciences Inc. (KOD) The Hot Biotech Stock Under $5?
Mar-10-25 04:39PM - Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy
Feb-04-25 07:30AM - Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025
Jan-13-25 04:26PM - Heres Why Kodiak Sciences Inc. (KOD) Is Skyrocketing
Jan-07-25 06:00AM - Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-01-10T14:35:00Z - Diabetic Retinopathy Global Clinical Trials Review 2024: Region, country (G7 & E7), phase, trial status, End-points Status and Sponsor Type
B2 - 2024-06-20T12:23:00Z - Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?
B3 - 2024-06-14T15:30:06Z - Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report?
B4 - 2024-05-16T16:51:00Z - Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
B5 - 2024-04-04T16:09:00Z - Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks
B6 - 2024-04-01T16:00:00Z - Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Kodiak Sciences (KOD).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

KOD_OUT_3 [2025-04-17 15:50:50 -0400] 697 Bytes | 189 tokens | Cum: 1239 tkns (15.49% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?**Date: Unknown DateSource: Unknown SourceURL: https://www.zacks.com/stock/news/2290807/should-you-hold-kodiak-sciences-kod-stock-in-your-portfolioKodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KOD_OUT_5 [2025-04-17 15:50:51 -0400] 830 Bytes | 254 tokens | Cum: 1495 tkns (18.69% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-05T11:54:31Z - HC Wainwright Forecasts Kodiak Sciences Q2 Earnings...
A2 - 2025-04-03T09:56:06Z - Brokers Set Expectations for Kodiak Sciences Q1 Earnings...
A3 - 2025-04-01T12:19:56Z - HC Wainwright Reiterates Neutral Rating for Kodiak Sciences (NASDAQ:KOD)...
A4 - 2025-03-28T21:47:14Z - Kodiak Sciences (NASDAQ:KOD) Posts Earnings Results, Beats Estimates By $0.06 EPS...
A5 - 2025-03-28T17:39:00Z - Economic Worries Hammer Stocks...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

KOD_OUT_7 [2025-04-17 15:50:52 -0400] 1181 Bytes | 354 tokens | Cum: 1851 tkns (23.14% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**HC Wainwright Forecasts Kodiak Sciences Q2 Earnings**Date: 2025-04-05Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/hc-wainwright-forecasts-kodiak-sciences-q2-earnings-2025-04-03/Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) - HC Wainwright issued their Q2 2025 EPS estimates for Kodiak Sciences in a report released on Monday, March 31st. HC Wainwright analyst M. Caufield forecasts that the company will earn ($0.99) per share for the quarter. HC Wainwright currently has a "Neutral" rating and a $3.00 target price on the stock. The consensus estimate for Kodiak Sciences' current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Kodiak Sciences' Q3 2025 earnings at ($1.10) EPS, Q4 2025 earnings at ($1.23) EPS, FY2025 earnings at ($4.23) EPS, FY2026 earnings at ($4.63) EPS, FY2

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KOD_OUT_9 [2025-04-17 15:50:53 -0400] 1181 Bytes | 335 tokens | Cum: 2188 tkns (27.35% of 8k)
==========================================================================

Showing A1 (chunk 2 of 5): 027 earnings at ($4.10) EPS and FY2028 earnings at ($2.90) EPS.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.84) EPS for the quarter, beating analysts' consensus estimates of ($0.90) by $0.06.

Separately, Jefferies Financial Group upgraded shares of Kodiak Sciences from a "hold" rating to a "buy" rating and set a $20.00 price objective on the stock in a research report on Monday, December 9th.

View Our Latest Stock Analysis on Kodiak Sciences

Kodiak Sciences Trading Up 4.3 %

Shares of KOD opened at $2.67 on Thursday. Kodiak Sciences has a 12-month low of $2.19 and a 12-month high of $11.60. The company has a market capitalization of $140.51 million, a PE ratio of -0.73 and a beta of 2.26. The business's 50 day moving average is $4.55 and its 200 day moving average is $5.43.

Institutional

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KOD_OUT_11 [2025-04-17 15:50:54 -0400] 1181 Bytes | 298 tokens | Cum: 2488 tkns (31.10% of 8k)
==========================================================================

Showing A1 (chunk 3 of 5): Trading of Kodiak Sciences

Several hedge funds have recently made changes to their positions in KOD. PNC Financial Services Group Inc. raised its position in Kodiak Sciences by 1,501.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company's stock valued at $32,000 after purchasing an additional 2,988 shares during the period. US Bancorp DE purchased a new stake in Kodiak Sciences in the 4th quarter worth about $40,000. Headlands Technologies LLC bought a new stake in shares of Kodiak Sciences during the 4th quarter worth approximately $90,000. JPMorgan Chase & Co. increased its stake in Kodiak Sciences by 220.9% in the third quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company's stock worth $117,000 after purchasing an additional 30,735 shares during the period. Finally, Fox Run Management L.L.C. purchased a new stake in shares

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KOD_OUT_13 [2025-04-17 15:50:55 -0400] 1182 Bytes | 281 tokens | Cum: 2771 tkns (34.64% of 8k)
==========================================================================

Showing A1 (chunk 4 of 5): of Kodiak Sciences during the fourth quarter valued at $118,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

About Kodiak Sciences (

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate r

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KOD_OUT_15 [2025-04-17 15:50:56 -0400] 1045 Bytes | 233 tokens | Cum: 3006 tkns (37.57% of 8k)
==========================================================================

Showing A1 (chunk 5 of 5): eporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Kodiak Sciences Right Now?

Before you consider Kodiak Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.

While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KOD_OUT_17 [2025-04-17 15:51:00 -0400] 1077 Bytes | 296 tokens | Cum: 3304 tkns (41.30% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-27 10-K ITEM 7. MGT DISC & ANALYS IS OF FIN COND & RESULTS OF OPER

You should read the following discussion and analysis of our financial condition and results of operations together with our CONS financial statements and the related notes in...

S2 - 2025-03-27 8-K Item 2.02 Results of Oper and Fin Cond.

On March 27, 2025, Kodiak Sciences Inc. (the Company) published a press release reporting the Companys financial results for the quarter and year ended December 31, 2024 and business highlights. A copy of the Companys pre...

S3 - 2024-11-14 10-Q PART IFINANCI AL INFO

Item 1. Financi al Stmnts (Unaudited).

Kodiak Sciences Inc.

Condensed Consolida ted Balance Sheets

(in thousands, except share and per share amounts)

(Unaudited)

September 30, 2024

December 31, 2023

Assets

Curr assets:

Cash...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

KOD_OUT_19 [2025-04-17 15:51:01 -0400] 1181 Bytes | 240 tokens | Cum: 3546 tkns (44.32% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYS IS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes included elsewhere in this Annual Report on Form 10-K. This discussion and analysis and other parts of this Annual Report on Form 10-K contain forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions, such as statements regarding our intentions, plans, objectives, expectations, forecasts and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including th

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KOD_OUT_21 [2025-04-17 15:51:01 -0400] 1181 Bytes | 256 tokens | Cum: 3804 tkns (47.55% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): ose set forth under the section titled Part I, Item 1A Risk Factors and elsewhere in this Annual Report on Form 10-K.

Overview

Kodiak Sciences (we, the Company or Kodiak) is a biopharmaceutical company committed to researching, developing, and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies and has been at the core of Kodiak's discovery engine. We are developing a portfolio of three clinical programs, two of which are late-stage today and derived from our ABC Platform and one which is platform-independent and which we believe can progress rapidly into pivotal studies

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KOD_OUT_23 [2025-04-17 15:51:02 -0400] 1181 Bytes | 283 tokens | Cum: 4089 tkns (51.11% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): .

Kodiak's lead investigational medicine, tarcocimab, is a novel anti-VEGF antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases. Tarcocimab is currently being studied in two Phase 3 clinical trials, GLOW2 in patients with diabetic retinopathy and DAYBREAK in patients with wet AMD. GLOW2 enrollment is complete, and DAYBREAK is actively enrolling patients.

KSI-501 is our second investigational medicine, a first-in-class anti-IL-6, VEGF-trap bispecific antibody biopolymer conjugate designed to inhibit both IL-6 mediated inflammation and VEGF-mediated angiogenesis and vascular permeability. KSI-501 is being developed for the treatment of high prevalence retinal vascular diseases to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. The Phase 3 DAYBREAK study of KSI

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KOD_OUT_25 [2025-04-17 15:51:05 -0400] 1181 Bytes | 279 tokens | Cum: 4370 tkns (54.62% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): -501 in wet AMD is actively enrolling patients.

KSI-101, our third product candidate, is a novel anti-IL-6, VEGF-trap bispecific protein. Kodiak is developing KSI-101 for the treatment of retinal inflammatory diseases, as currently there are no available intravitreal biologic therapies addressing the spectrum of inflammatory conditions of the retina. The Phase 1b APEX study of KSI-101 is actively enrolling patients, as a precursor to activating the Phase 2b/3 studies in patients with macular edema secondary to inflammation (MESI).

Kodiak is advancing its platform technology to embed small molecules and other active pharmaceutical ingredients ("APIs") into Kodiak's proprietary biopolymer backbone to enable high drug-antibody-ratio ("DAR") medicines. The diverse APIs are designed to be released over time to achieve targeted, multi-specific and tailored modulation of biological pathways

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KOD_OUT_27 [2025-04-17 15:51:06 -0400] 1181 Bytes | 257 tokens | Cum: 4629 tkns (57.86% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): . The unique combination of high DAR and tailored therapeutic benefit offers potential for broad application to multifactorial diseases and builds directly from our Antibody Biopolymer Conjugate technology and its 15 years of design, development and manufacturing experience. We call this platform extension our Antibody Biopolymer Conjugate Drug (ABCD) Platform because we are extending our platform capabilities to include the conjugation of small molecule drugs whereas historically we conjugated biologics such as antibodies.

Recent Updates

Tarcocimab Clinical Program Summary and Update

Kodiaks lead clinical program tarcocimab is an investigational anti-VEGF therapy built on Kodiaks ABC Platform and is designed to maintain potent and effective drug levels in ocular tissues for longer than existing available agents. It is being developed as a mainstay intravitreal biologic monotherapy

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KOD_OUT_29 [2025-04-17 15:51:07 -0400] 790 Bytes | 182 tokens | Cum: 4813 tkns (60.16% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): intended to provide high immediacy, driven by the enhanced formulation, and high durability, driven by the ABC Platform and our science of durability, with the ultimate objective of providing, once approved, a flexible 1-month through 6-month label. Kodiaks objective with tarcocimab is to enable earlier treatment and prevention of vision loss for patients with diabetic retinopathy and to develop a new high immediacy and high durability agent to improve outcomes for patients with retinal vascular di...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KOD_OUT_31 [2025-04-17 15:51:13 -0400] 5922 Bytes | 1567 tokens | Cum: 6384 tkns (79.80% of 8k)
==========================================================================

This is our set of metrics for Kodiak Sciences.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+----------------------+
| Volume: 518,282 | Perf Month: -16.72% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+-------------------------+----------------------+
| Avg Volume: 361.33K | Perf Quarter: -63.48% | Short Float: 6.56% | ROE: -84.70% |
+---------------------+-----------------------+-------------------------+----------------------+
| Rel Volume: 1.53 | Index: RUT | Short Ratio: 8.82 | ROI: -56.84% |
+---------------------+-----------------------+-------------------------+----------------------+
| RSI (14): 47.85 | Market Cap: 147.17M | Short Interest: 3.19M | Sales Surprise: - |
+---------------------+-----------------------+-------------------------+----------------------+
| ATR (14): 0.30 | Shs Outstand: 52.73M | Beta: 2.51 | EPS Surprise: 4.90% |
+---------------------+-----------------------+-------------------------+----------------------+
| SMA20: 6.85% | Shs Float: 48.62M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+-------------------------+----------------------+
| SMA50: -22.25% | Inst Own: 77.78% | Sales past 5Y: 0.00% | Earnings: Mar 27 AMC |
+---------------------+-----------------------+-------------------------+----------------------+
| SMA200: -37.47% | Insider Own: 7.83% | Employees: 109 | |
+---------------------+-----------------------+-------------------------+----------------------+
| Perf Week: 33.17% | Insider Trans: 0.00% | Debt/Eq: 1.13 | |
+---------------------+-----------------------+-------------------------+----------------------+

The next section covers any insider trading by Kodiak Sciences officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -176207000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.855
Average Volume: 402311.0
30-Day High: 3.52
30-Day Low: 2.06

[Detailed Financials: TTM 2024]
- Total Assets: $335,578,000.00
- Total Liabilities: $185,290,000.00
- Total Equity: $150,288,000.00
- Current Assets: $171,936,000.00
- Current Liabilities: $25,573,000.00

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: $-176,207,000.00
- Gross Profit: N/A
- Operating Income: $-186,849,000.00
- Earnings Per Share (EPS): -3.35

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-117,573,000.00

[Detailed Financials: FY 2024]
- Total Assets: $335,578,000.00
- Total Liabilities: $185,290,000.00
- Total Equity: $150,288,000.00
- Current Assets: $171,936,000.00
- Current Liabilities: $25,573,000.00

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: $-176,207,000.00
- Gross Profit: N/A
- Operating Income: $-186,849,000.00
- Earnings Per Share (EPS): -3.35

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-117,573,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Kodiak Sciences (KOD).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Kodiak Sciences.

2) MARKET_SCORE[]
This conversation was initiated because KOD is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for KOD.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, KOD could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect KOD to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Kodiak Sciences.

11) ETHICAL_RATING[]
Rate Kodiak Sciences’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Kodiak Sciences.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

KOD_IN_33 [2025-04-17 15:51:13 -0400] 126 Bytes | 29 tokens | Cum: 6621 tkns (82.76% of 8k)
==========================================================================

====================================
[2025-04-17 15:51:13] # Analysis Completed
Elapsed Time: 26.96 seconds